ClinicalTrials.gg
CompletedNCT03036345Updated Nov 4, 2026

Cerebral Perfusion in the Beach Chair Position

An interventional study of Dual-monitoring in Cognitive Dysfunction, sponsored by Brisbane Hand and Upper Limb Research Institute. Completed at 1 site in Australia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Brisbane Hand and Upper Limb Research Institute · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 4, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Cognitive Dysfunction with a site in Australia — 12 open to participants now, 22 under way, 9 of them phase 3. Cognitive Dysfunction · Australia.

Enrollment
22nd of 51
200 · median 167
Started
2017
with 2 others
No phase
15 of 57
4 open now
Registered
19th of 57
by date

Among the 57 studies in Cognitive Dysfunction with a site in Australia, this one is the 22nd largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2017, is one of 15 with no phase, and was the 19th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

12 of the 57 studies in Cognitive Dysfunction with a site in Australia are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Cognitive Dysfunction with a site in Australia, or all of them as a file.
02

Study summary

Surgery to the shoulder may be performed with patients seated upright in a position known as the "Beach Chair Position (BCP)." This position has certain advantages compared to alternative surgical positions (e.g. side lying) in some situations. However, it has been found that surgery in the BCP can temporarily decrease the amount of oxygen in the brain as a result of the combined effects of gravity and anaesthesia. This can result in complications following surgery such as some memory loss and confusion. Rarely, more serious complications have been reported in the past including death and stroke.

Due to these reported complications the use of "cerebral oximetry" during shoulder surgery in the BCP has become more common. Before and during surgery, a monitor placed on the patients forehead measures the amount of oxygen present in the brain to help control this to an acceptable level. A number of monitors are now commercially available. Two monitors are commonly discussed in the literature; the INVOS™ 5100 and the FORE-SIGHT® machines. However, the actual relationship between the supply of oxygen to the brain during surgery and the chance of later developing problems with memory and thinking (known as "post operative cognitive decline" - POCD) is not clear. It is also not known if one monitor is more accurate than another at predicting these complications.

Therefore, the main aim of this study is to examine the relationship between cerebral oxygen levels during shoulder surgery and the incidence of POCD (i.e. problems with memory and thinking). A second aim is to compare the INVOS™ 5100 and FORE-SIGHT® monitors ability to measure cerebral oxygen and cerebral desaturation events (CDEs) as well as the importance of other key clinical variables (e.g. blood pressure, nausea, body fat etc).

Read the detailed description

PURPOSE OF THE INVESTIGATION The purpose of this investigation is to generate evidence about cerebral oxygenation during shoulder surgery and the incidence of POCD. Currently, evidence relating to POCD following surgery is conflicting and relates mostly to outcomes following cardiac surgery. There is a strong need to explore this relationship in the specific context of shoulder surgery in the BCP.

INTERVENTION GROUPS This study will involve a single prospective cohort. Patients who meet the selection criteria will be recruited to the study following voluntary informed consent . Cerebral oxygenation will be measured by application of cerebral oximeters to each patients forehead.

AIM OF THE STUDY This study has three aims; (i) To examine the relationship between cerebral desaturation during shoulder surgery in the BCP, and the incidence of POCD.

(ii) To determine the variation in cerebral oxygenation recorded using randomised (for superior/inferior) simultaneous application of the INVOS™ and FORE-SIGHT® oximeters, during shoulder surgery in the beach chair position.

(iii) Assess the relationships between cerebral oxygen desaturation during shoulder surgery in the BCP and variables including mean arterial pressure, incidence of nausea/vomiting, duration of hospital stay, BMI, hypertension and adverse events.

RESEARCH QUESTION There are three research questions correlating with the three research aims; (i) Is cerebral desaturation during shoulder surgery associated with POCD? (ii) Do the FORE-SIGHT® and INVOS™ 5100 devices vary in their measurement of cerebral oxygenation during shoulder surgery in the BCP? (iii) Is there a relationship between cerebral desaturation events during shoulder surgery in the BCP and variables including mean arterial blood pressure, post-operative nausea/vomiting, length of hospital stay, BMI, hypertension and any adverse events?

NULL HYPOTHESES The three null hypotheses are; (i) Cerebral desaturation as measured using cerebral oximetry is not related to POCD after shoulder surgery in the BCP.

(ii) There is no significant difference between the INVOS™ 5100 and the FORE-SIGHT® monitors assessment of cerebral oxygenation during shoulder surgery in the BCP.

(iii) There is no relationship between cerebral desaturation events during shoulder surgery in the BCP and variables including mean arterial blood pressure, the frequency of post-operative nausea/vomiting, length of hospital stay, BMI, hypertension and any adverse events.

PRIMARY HYPOTHESES The primary research hypotheses are; (i) Cerebral desaturation events during surgery in the BCP will be related to POCD.

(ii) The INVOS™ 5100 and the FORE-SIGHT® monitors will show no significant difference in their ability to measure cerebral oxygenation.

(iii) Cerebral desaturation events experienced during shoulder surgery in the BCP are related to a drop in mean arterial blood pressure, an increased likelihood of post-operative nausea and vomiting, greater length of hospital stay, a higher BMI, hypertension and greater frequency of adverse events.

03

Conditions studied

  • Cognitive Dysfunction
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving treatment primarily by, but not restricted to, one of the Primary investigators for a shoulder condition that requires surgery in the BCP.
  • Over 18 years of age
  • Able to read and speak English

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age
  • Pregnant women
  • Pre-operative (MMSE) \< 24
  • Pre-existing cerebrovascular disease as reported by the assessing medical consultant and recorded in patient charts
  • Orthostatic hypotension
  • American Society of Anaesthesiologists (ASA) physical status III, IV and V*
  • History of drug and/or alcohol abuse
  • Neurological disease (e.g. previous stroke)
  • Significant mood and anxiety disorders as determined by treating consultant.
  • Any other condition, which in the opinion of the investigators, would render the patient unsuitable for participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Surgery patients

    Patients receiving shoulder surgery in the Beach Chair Position, and monitored by both INVOS and FORE-SIGHT monitors.

    Device: Dual-monitoring

Interventions

  • DeviceDual-monitoring

    Monitored using both INVOS and FORE-SIGHT monitors.

06

What researchers measure

Primary outcomes

  1. Trail making test: Delis-Kaplan Executive Function System

    The D-KEFs Trails subtest has four trials; visual scanning, number sequencing, letter sequencing and letter number sequencing.

    Time frame: Baseline

  2. Trail making test: Delis-Kaplan Executive Function System

    The D-KEFs Trails subtest has four trials; visual scanning, number sequencing, letter sequencing and letter number sequencing.

    Time frame: 1 day post-operative

  3. Trail making test: Delis-Kaplan Executive Function System

    The D-KEFs Trails subtest has four trials; visual scanning, number sequencing, letter sequencing and letter number sequencing.

    Time frame: 8-14 days post-operative

  4. Trail making test: Delis-Kaplan Executive Function System

    The D-KEFs Trails subtest has four trials; visual scanning, number sequencing, letter sequencing and letter number sequencing.

    Time frame: 6 weeks post-operative

  5. Trail making test: Delis-Kaplan Executive Function System

    The D-KEFs Trails subtest has four trials; visual scanning, number sequencing, letter sequencing and letter number sequencing.

    Time frame: 3 months post-operative

  6. Single letter verbal fluency

    This task requires the individual to spontaneously generate a list of words in 60 seconds, where the words cannot be name of places, people or other proper nouns.

    Time frame: Baseline

  7. Single letter verbal fluency

    This task requires the individual to spontaneously generate a list of words in 60 seconds, where the words cannot be name of places, people or other proper nouns.

    Time frame: 1 day post-operative

  8. Single letter verbal fluency

    This task requires the individual to spontaneously generate a list of words in 60 seconds, where the words cannot be name of places, people or other proper nouns.

    Time frame: 8-14 days post-operative

  9. Single letter verbal fluency

    This task requires the individual to spontaneously generate a list of words in 60 seconds, where the words cannot be name of places, people or other proper nouns.

    Time frame: 6 weeks post-operative

  10. Single letter verbal fluency

    This task requires the individual to spontaneously generate a list of words in 60 seconds, where the words cannot be name of places, people or other proper nouns.

    Time frame: 3 months post-operative

  11. Rey Auditory Verbal Learning Test

    The RAVLT assesses immediate and delayed auditory memory recall and recognition. The task consists of 15 nouns learned over 5 trials with a free recall after each presentation. The order of presentation remaining fixed across trials (List A). At the end of the 5th trial an interference list of 15 words is presented (List B), following a free recall of that list. Immediately after this, delayed recall of the first list is tested. Following a 20-minute delay, delayed recall and recognition of the first word list is assessed.

    Time frame: Baseline

  12. Rey Auditory Verbal Learning Test

    The RAVLT assesses immediate and delayed auditory memory recall and recognition. The task consists of 15 nouns learned over 5 trials with a free recall after each presentation. The order of presentation remaining fixed across trials (List A). At the end of the 5th trial an interference list of 15 words is presented (List B), following a free recall of that list. Immediately after this, delayed recall of the first list is tested. Following a 20-minute delay, delayed recall and recognition of the first word list is assessed.

    Time frame: 1 day post-operative

  13. Rey Auditory Verbal Learning Test

    The RAVLT assesses immediate and delayed auditory memory recall and recognition. The task consists of 15 nouns learned over 5 trials with a free recall after each presentation. The order of presentation remaining fixed across trials (List A). At the end of the 5th trial an interference list of 15 words is presented (List B), following a free recall of that list. Immediately after this, delayed recall of the first list is tested. Following a 20-minute delay, delayed recall and recognition of the first word list is assessed.

    Time frame: 8-14 days post-operative

  14. Rey Auditory Verbal Learning Test

    The RAVLT assesses immediate and delayed auditory memory recall and recognition. The task consists of 15 nouns learned over 5 trials with a free recall after each presentation. The order of presentation remaining fixed across trials (List A). At the end of the 5th trial an interference list of 15 words is presented (List B), following a free recall of that list. Immediately after this, delayed recall of the first list is tested. Following a 20-minute delay, delayed recall and recognition of the first word list is assessed.

    Time frame: 6 weeks post-operative

  15. Rey Auditory Verbal Learning Test

    The RAVLT assesses immediate and delayed auditory memory recall and recognition. The task consists of 15 nouns learned over 5 trials with a free recall after each presentation. The order of presentation remaining fixed across trials (List A). At the end of the 5th trial an interference list of 15 words is presented (List B), following a free recall of that list. Immediately after this, delayed recall of the first list is tested. Following a 20-minute delay, delayed recall and recognition of the first word list is assessed.

    Time frame: 3 months post-operative

  16. Letter-Number Sequencing (from Wechsler Adult Intelligence Scale, 4th edition)

    The examinee is verbally presented with a combination of numbers and letters or increasing amounts. The examinee is required to recall the numbers in ascending order then letters in alphabetical order.

    Time frame: Baseline

  17. Letter-Number Sequencing (from Wechsler Adult Intelligence Scale, 4th edition)

    The examinee is verbally presented with a combination of numbers and letters or increasing amounts. The examinee is required to recall the numbers in ascending order then letters in alphabetical order.

    Time frame: 1 day post-operative

  18. Letter-Number Sequencing (from Wechsler Adult Intelligence Scale, 4th edition)

    The examinee is verbally presented with a combination of numbers and letters or increasing amounts. The examinee is required to recall the numbers in ascending order then letters in alphabetical order.

    Time frame: 8-14 days post-operative

  19. Letter-Number Sequencing (from Wechsler Adult Intelligence Scale, 4th edition)

    The examinee is verbally presented with a combination of numbers and letters or increasing amounts. The examinee is required to recall the numbers in ascending order then letters in alphabetical order.

    Time frame: 6 weeks post-operative

  20. Letter-Number Sequencing (from Wechsler Adult Intelligence Scale, 4th edition)

    The examinee is verbally presented with a combination of numbers and letters or increasing amounts. The examinee is required to recall the numbers in ascending order then letters in alphabetical order.

    Time frame: 3 months post-operative

Secondary outcomes

  1. Cerebral desaturation events (INVOS)

    Cerebral desaturation will be defined as a decrease in regional cerebral oxygen saturation greater than, or equal to 20% from baseline or a fall below 50% absolute.

    Time frame: Intra-operative

  2. Cerebral desaturation events (FORE-SIGHT)

    Cerebral desaturation will be defined as a decrease in regional cerebral oxygen saturation greater than, or equal to 20% from baseline or a fall below 50% absolute.

    Time frame: Intra-operative

  3. Mean arterial pressure

    Mean arterial blood pressure (mmHg)

    Time frame: Intra-operative

  4. Body Mass Index

    Patient Body Mass Index (BMI)

    Time frame: Baseline

  5. Hypertension

    Patient-reported hypertension

    Time frame: Baseline

  6. Nausea and vomiting within 48 hours

    Patient-reported nausea and vomiting

    Time frame: 1 day, 8-14 days

  7. Duration of hospital stay

    Patient duration of hospital stay

    Time frame: 8-14 days

  8. Adverse events

    Any adverse events arising during the trial will be closely monitored and followed up until the resolution of symptoms. These will be checked at each assessment stage and recorded on a data collection form.

    Time frame: Intra-operative

  9. Adverse events

    Any adverse events arising during the trial will be closely monitored and followed up until the resolution of symptoms. These will be checked at each assessment

    Time frame: 1 day

  10. Adverse events

    Any adverse events arising during the trial will be closely monitored and followed up until the resolution of symptoms. These will be checked at each assessment

    Time frame: 8-14 days

  11. Adverse events

    Any adverse events arising during the trial will be closely monitored and followed up until the resolution of symptoms. These will be checked at each assessment

    Time frame: 6 weeks

  12. Adverse events

    Any adverse events arising during the trial will be closely monitored and followed up until the resolution of symptoms. These will be checked at each assessment

    Time frame: 3 months

Other outcomes

  1. Depression Anxiety and Stress Scale-21

    The DASS-21 has 21 questions that index the level of depression, anxiety and stress an individual has experienced in the preceding week.

    Time frame: Baseline, 1 day, 8-14 days, 6 weeks, 3 months

  2. Social Relationships and Support Scale

    The social support measures address the issues of social process in a range different clinical populations.

    Time frame: Baseline, 1 day, 8-14 days, 6 weeks, 3 months

  3. Loneliness Scale

    A standardised 3-item Loneliness scale, comprised of items from the well-validated University of California, Los Angeles (UCLA) Loneliness scale.

    Time frame: Baseline, 1 day, 8-14 days, 6 weeks, 3 months

07

Study locations

1 site
  • Brisbane Hand and Upper Limb Research Institute, Brisbane Private Hospital
    Brisbane, Queensland 4000, Australia
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified cerebral oximeter data acquisition files will be made available to the equipment manufacturers (Medtronic, CASMED) at the conclusion of the study.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jun 2020, 36 months.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 36 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Dec 2019 → Jun 2020 and completion Jun 2020 → Oct 2020.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2016
First posted
Jan 30, 2017
StartActual
May 25, 2017
Primary completionActual
Jun 18, 2020was Dec 2019
CompletionActual
Oct 31, 2020was Jun 2020
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 4, 2026
Primary completion
Dec 2019→Jun 18, 2020 (actual)
Nov 4, 2026
Study completion
Jun 2020→Oct 31, 2020 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Status unknown→Completed
    Primary completion Dec 2019→Jun 18, 2020 (now actual)
    Study completion Jun 2020→Oct 31, 2020 (now actual)
    + 4 other changes: index terms, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03036345
Lead sponsor
Brisbane Hand and Upper Limb Research Institute
Collaborators
Medtronic, CAS Medical Systems, Inc.
Responsible party
Sponsor
First posted
Jan 30, 2017
Start date
May 25, 2017
Primary completion
Jun 18, 2020
Completion
Oct 31, 2020
Last update
Nov 4, 2026

Study contacts

Mark Ross, MBBS
principal investigator · Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion